A long-term study involving more than 2,600 women found higher rates of anxiety and depressive symptoms among those who had reached advanced stages of the menopausal transition by age 46, highlighting the importance of monitoring emotional health during hormonal changes.

By yourNEWS Media Newsroom

Women who enter the later stages of the menopausal transition earlier than usual may face an increased likelihood of anxiety and depressive symptoms, according to new research from Finland that followed participants through middle age and examined both their emotional health and psychiatric medication use.

The investigation, conducted by researchers at the University of Oulu, found that women who had reached late perimenopause or menopause by age 46 reported significantly more psychological symptoms than women of the same age who had not reached those stages.

The findings, published in the journal Acta Obstetricia et Gynecologica Scandinavica, suggest that the timing of menopause may be an important consideration when evaluating women’s mental health, although researchers cautioned that the results do not establish that hormonal changes directly cause anxiety or depression.

The study, titled Menopausal Status at the Age of 46: Its Association With Depressive and Anxiety Symptoms and Morbidity in Women, examined 2,632 participants from the Northern Finland Birth Cohort 1966, a long-running population study that has tracked individuals born in northern Finland.

At age 46, approximately 13% of the women, or 356 participants, had already entered more advanced stages of the menopausal transition.

Among those women, 22.6% reported clinically significant anxiety symptoms, compared with 16% of participants who had not reached the same menopausal stage.

Depressive symptoms followed a similar pattern, affecting 30.1% of women in the earlier-transition group compared with 24.6% of those who remained premenopausal or had not entered advanced perimenopause.

The associations remained statistically significant after researchers accounted for smoking, alcohol consumption, body mass index and educational attainment.

After those adjustments, women who had reached advanced menopausal stages at age 46 had 44% higher odds of significant anxiety symptoms and 39% higher odds of depressive symptoms on one of the study’s screening measures.

Those findings indicate an association between menopausal timing and mental health symptoms, rather than a diagnosis of a psychiatric disorder in every participant reporting elevated scores.

The results also require an important distinction between menopause and the broader menopausal transition.

Menopause is generally defined retrospectively after 12 consecutive months without menstruation, provided the absence of periods is not attributable to another medical condition.

Perimenopause refers to the transitional period preceding menopause, when ovarian hormone production becomes increasingly variable and menstrual cycles may become irregular.

This transition can last several years and is frequently accompanied by hot flashes, night sweats, sleep disturbances and changes in emotional well-being.

The average age of natural menopause among Finnish women is approximately 51, according to the University of Oulu’s October 5 announcement.

Consequently, participants who had reached advanced stages by age 46 were experiencing those changes earlier than the population average.

To assess the relationship, researchers considered hormone measurements, menstrual histories and hormone therapy use when determining menopausal stage.

Participants also completed standardized questionnaires measuring anxiety and depression.

The Hopkins Symptom Checklist-25 was used to evaluate psychological symptoms, while the Beck Depression Inventory provided another assessment of depressive symptoms.

The researchers additionally examined Finnish national prescription records to determine whether participants purchased antidepressants or anxiety-related medications between ages 40 and 57.

The medication data showed that 48% of women in the advanced menopausal group purchased antidepressants during that period, compared with 41% of women in the comparison group.

Purchases of benzodiazepine-derived medications were also more common among women who had experienced earlier menopausal changes, at 18.3% compared with 13.3%.

However, those medication associations were no longer independently significant after the researchers adjusted for multiple background characteristics.

The finding suggests that factors beyond menopausal timing may help explain differences in psychiatric medication use.

Medication purchases also do not necessarily establish that a patient had a particular psychiatric diagnosis, because some drugs are prescribed for other medical conditions.

The investigators found that women entering advanced menopausal stages earlier differed from their peers in several respects.

They were more likely to smoke, less likely to have completed higher education and more likely to have no children.

Such differences can influence psychological health independently of hormonal changes, making it important to account for them when interpreting the results.

The researchers adjusted for several of these characteristics, but acknowledged that other unmeasured factors could contribute to the observed associations.

Their conclusions build on broader scientific interest in how changing reproductive hormones interact with the nervous system.

Estrogen influences neurotransmitter systems associated with mood, including serotonin and dopamine, while hormonal fluctuations may affect emotional regulation and sensitivity to stress.

During perimenopause, estrogen levels can vary substantially rather than declining in a steady, predictable pattern.

Those fluctuations may coincide with changes in sleep quality, temperature regulation and overall well-being.

For some women, persistent night sweats or hot flashes can interrupt sleep repeatedly, potentially contributing to irritability, fatigue and difficulty concentrating.

Sleep disturbances may also worsen existing anxiety or depressive symptoms.

However, researchers have not established a simple, consistent relationship among estrogen levels, cortisol production and psychological distress.

Some studies have identified associations between hormonal changes and stress responses, while others have found little difference in cortisol levels between premenopausal and postmenopausal women.

Research examining estrogen-progestin treatment has likewise produced mixed findings concerning cortisol regulation.

A 2025 Finnish study published in Maturitas found that sleep quality, cardiovascular factors, body weight and stressful life events were associated with anxiety symptoms among postmenopausal women.

Those findings reinforce the view that mental health during menopause is influenced by several interacting biological and social factors.

Other research has examined whether menopausal hormone therapy can improve mood symptoms in selected patients.

Some clinical trials suggest that estrogen treatment may help certain women experiencing depressive symptoms during perimenopause, particularly when symptoms occur alongside significant vasomotor disturbances.

Nevertheless, hormone therapy is not recommended as a universal treatment for depression, and its suitability depends on individual medical history, symptoms, age and potential risks.

Evidence concerning hormonal treatment for anxiety and depressive disorders remains mixed, making individualized clinical evaluation important.

For women with persistent mood symptoms, treatment may involve psychotherapy, established psychiatric medications, management of sleep disturbances or other interventions based on the circumstances.

Hormone therapy may be discussed when appropriate, especially when bothersome menopausal symptoms are present, but it should not replace necessary evaluation or treatment of a mental health condition.

The timing of menopause may also have implications beyond emotional health.

Earlier menopause is associated with longer exposure to lower estrogen levels, which may influence bone density and cardiovascular health.

The Cleveland Clinic’s guidance on menopause identifies osteoporosis and cardiovascular disease among the health concerns associated with the postmenopausal period.

However, those risks vary according to age at menopause, overall health, lifestyle and other individual characteristics.

The Finnish researchers emphasized that awareness of potential mental health symptoms should be part of broader menopause care.

Women experiencing earlier-than-expected menstrual changes may benefit from discussing those changes with a health professional, particularly when accompanied by persistent anxiety, sadness, sleep disruption or reduced quality of life.

Clinicians can consider whether symptoms are related to menopausal changes, an existing mental health condition, thyroid dysfunction, medication effects or other medical and social factors.

The study’s observational design prevents researchers from determining whether earlier menopause itself caused the increased psychological symptoms.

It is also possible that shared biological, environmental or lifestyle factors contributed to both menopausal timing and mental health differences.

Nevertheless, the consistency of the anxiety findings after adjustment for several major confounders suggests that the association warrants further investigation.

The researchers concluded that women experiencing earlier menopausal changes may represent a group that would benefit from greater attention to emotional well-being.

Their findings support integrating mental health discussions into routine care during midlife rather than treating anxiety, depression and menopausal symptoms as entirely unrelated concerns.

For women noticing changes in mood or anxiety during perimenopause, the research provides additional evidence that such experiences deserve clinical attention.

The results do not suggest that depression or anxiety is inevitable during menopause. Instead, they highlight an increased likelihood of symptoms among women reaching advanced menopausal stages earlier and the importance of identifying concerns before they substantially affect daily life.

Explainer Infographic

Source: Natural News
Original article
Add as a preferred source on Google